From overtreating good-risk patients to searching for a cure, Adam Kittai, MD, Perlmutter Cancer Center, outlines where CLL ...

Jaypirca demonstrated superior overall response rates and progression-free survival trends compared to Imbruvica in the BRUIN CLL-314 trial for CLL/SLL patients. The trial is the first head-to-head ...

Pirtobrutinib, a highly selective, noncovalent Bruton’s tyrosine kinase inhibitor (BTKi), shows substantial improvements in progression-free survival over the chemotherapy regimen of bendamustine plus ...

Jaypirca showed higher overall response rates than Imbruvica in both treatment-naive and relapsed/refractory CLL/SLL populations. Progression-free survival trends favored Jaypirca, especially in ...

Patients receiving zanubrutinib experienced a longer time to next treatment, indicating more durable disease control in routine practice.

New data presented at EHA 2026 showed durable long-term outcomes for BRUKINSA in patients aged 80 and older, while additional real-world analyses reinforced its competitive position in chronic ...

The study included 639 patients, 79.8% of whom had previously received covalent BTK inhibitors.

Propensity-matched TriNetX cohorts (669 pairs) of TP53–wild-type, treatment-naive CLL showed venetoclax–obinutuzumab improved TTNT and 4-year OS versus acalabrutinib (HR 1.84). Median TTNT was 47.7 ...

BeOne Medicines’ wholly owned, all-oral combination of Beqalzi (sonrotoclax) plus Brukinsa (zanubrutinib) was investigated as ...

Copiktra (duvelisib) is a type of cancer treatment for certain people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). CLL and SLL are slow-growing cancers that affect a ...

ISTANBUL, TR / ACCESS Newswire / June 17, 2026 / Lymphocytic leukemia is a type of blood cancer that affects lymphocytes, a ...

Expert Rev Hematol. 2013;6(4):441-449. The newest biological variables of prognostic relevance are useful for understanding the clinical heterogeneity of disease, however, their value at the time of ...